Hiding in plain sight: An approach to treating patients with severe covid-19 infection

mBio

Volumn 11, Issue 2, 2020, Pages

  Fedson, David S ^a   Opal, Steven M ^b   Rordam, Ole Martin ^c  

^a Warren Alpert Medical School of Brown University ^*  (France)

^b BROWN UNIVERSITY   (United States)

^c NONE   (Norway)

Author keywords

COVID 19; Endothelial dysfunction; Generic drugs; Host response treatment

Indexed keywords

ANGIOPOIETIN; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN[1-7]; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MONOCLONAL ANTIBODY; AGTR2 PROTEIN, HUMAN; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CORONAVIRUS RECEPTORS; DIPEPTIDYL CARBOXYPEPTIDASE; VIRUS RECEPTOR;

ACUTE LUNG INJURY; ACUTE RESPIRATORY DISEASE SYNDROME; ACUTE RESPIRATORY TRACT DISEASE; ARTICLE; CLINICAL TRIAL (TOPIC); CORONAVIRUS DISEASE 2019; CORONAVIRUS INFECTION; CRITICALLY ILL PATIENT; DEATH; DEMOCRATIC REPUBLIC CONGO; DISEASE SEVERITY; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; ENDOTHELIAL DYSFUNCTION; EPIDEMIC; FATALITY; IMMUNE RESPONSE; INFECTION CONTROL; NETHERLANDS; PATIENT CARE; PNEUMONIA; PRIORITY JOURNAL; QUARANTINE; RISK FACTOR; SARS CORONAVIRUS; SEASONAL INFLUENZA; UPREGULATION; VIRUS REPLICATION; BETACORONAVIRUS; BIOSYNTHESIS; HUMAN; METABOLISM; VIROLOGY; VIRUS PNEUMONIA;

ANGIOTENSIN II TYPE 2 RECEPTOR BLOCKERS; BETACORONAVIRUS; CORONAVIRUS INFECTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PEPTIDYL-DIPEPTIDASE A; PNEUMONIA, VIRAL; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, VIRUS;

EID: 85082136047     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00398-20     Document Type: Article

References (19)

1. Chen Y, Liu Q, Guo D. 2020. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol 92:418–423. https://doi.org/10.1002/jmv.25681.
2. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. 7 February 2020. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA https://doi.org/10.1001/jama.2020.1585.
3. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. 2020. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. China CDC Weekly 2:113–122. http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51. Accessed 18 February 2020.
4. Fedson DS. 2015. A practical treatment for patients with Ebola virus disease. J Infect Dis 21:661– 662. https://doi.org/10.1093/infdis/jiu474.
5. Shyamsundar M, McKeown STW, O’Kane CM, Craig TR, Brown V, Thickett DR, Matthay MA, Taggart CC, Backman JT, Elborn JS, McAuley DF. 2009. Simvastatin decreases lipopoly-saccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med 179:1107–1114. https://doi.org/10.1164/rccm.200810-1584OC.
6. Chen W, Sharma R, Rizzo AN, Siegler JH, Garcia JG, Jacobson JR. 2014. Role of claudin-5 in the attenuation of murine acute lung injury by simvastatin. Am J Respir Cell Mol Biol 50:328–336. https://doi.org/10.1165/rcmb.2013-0058OC.
7. Shen L, Mo H, Cai L, Kong T, Zheng W, Ye J, Qi J, Xiao Z. 2009. Losartan prevents sepsis-induced acute lung injury and decreases activation of nuclear factor kappaB and mitogen-activated protein kinases. Shock 3:500 –506. https://doi.org/10.1097/SHK.0b013e318189017a.
8. Li Y, Cao Y, Zeng Z, Liang M, Xue Y, Xi C, Zhou M, Jiang W. 2015. Angiotensin-converting enzyme 2/angiotensin-(1–7)/Mas axis prevents lipopolysaccharide-induced apoptosis of pulmonary microvascular endothelial cells by inhibiting JNK/NF-B pathways. Sci Rep 5:8209. https://doi.org/10.1038/srep08209.
9. Fedson DS. 2016. Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola. Ann Transl Med 4:421. https://doi.org/10.21037/atm.2016.11.03.
10. Fedson DS, Jacobson JR, Rordam OM, Opal SM. 2015. Treating the host response to Ebola virus disease with generic statins and angiotensin receptor blockers. mBio 6:e00716-15. https://doi.org/10.1128/mBio.00716-15.
11. Fedson DS, Rordam OM. 2015. Treating Ebola patients: a ‘bottom up’ approach using generic statins and angiotensin receptor blockers. Int J Infect Dis 36:80 – 84. https://doi.org/10.1016/j.ijid.2015.04.019.
12. Mulangu S, Dodd LE, Davey RT, Jr, Tshiani Mbaya O, Proschan M, Mukadi D, Lusakibanza Manzo M, Nzolo D, Tshomba Oloma A, Ibanda A, Ali R, Coulibaly S, Levine AC, Grais R, Diaz J, Lane HC, Muyembe-Tamfum JJ, PALM Writing Group, Sivahera B, Camara M, Kojan R, Walker R, Dighero-Kemp B, Cao H, Mukumbayi P, Mbala-Kingebeni P, Ahuka S, Albert S, Bonnett T, Crozier I, Duvenhage M, Proffitt C, Teitelbaum M, Moench T, Aboulhab J, Barrett K, Cahill K, Cone K, Eckes R, Hensley L, Herpin B, Higgs E, Ledgerwood J, Pierson J, Smolskis M, Sow Y, Tierney J, Siva-palasingam S, Holman W, Gettinger N, Vallée D, Nordwall J, PALM Consortium Study Team. 2019. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 381:2293–2303. https://doi.org/10.1056/NEJMoa1910993.
13. Fedson DS. 2019. Treating Ebola in eastern DRC. Lancet Infect Dis 19:1059–1060. https://doi.org/10.1016/S1473-3099(19)30484-0.
14. Wösten-van Asperen RM, Lutter R, Specht PA, Moll GN, van Woensel JB, van der Loos CM, van Goor H, Kamilic J, Florquin S, Bos AP. 2011. Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1–7) or an angiotensin II receptor antagonist. J Pathol 225:618 – 627. https://doi.org/10.1002/path.2987.
15. Tikoo K, Patel G, Kumar S, Karpe PA, Sanghavi M, Malek V, Srinivasan K. 2015. Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications. Biochem Pharmacol 93:343–351. https://doi.org/10.1016/j.bcp.2014.11.013.
16. Wösten-van Asperen RM, Bos AP, Bem RA, Dierdorp BS, Dekker T, van Goor H, Kamilic J, van der Loos CM, van den Berg E, Bruijn M, van Woensel JB, Lutter R. 2013. Imbalance between pulmonary angiotensin-0,2020 converting enzyme and angiotensin-converting enzyme 2 activity in acute respiratory distress syndrome. Pediatr Crit Care Med 14: e438 – e441. https://doi.org/10.1097/PCC.0b013e3182a55735.
17. Steinberg BE, Goldenberg NM, Lee WL. 2012. Do viral infections mimic bacterial sepsis? The role of microvascular permeability: a review of mechanisms and methods. Antiviral Res 93:2–15. https://doi.org/10.1016/j.antiviral.2011.10.019.
18. Pirofski LA, Casadevall A. 2018. The Damage-Response Framework as a tool for the physician-scientist to understand the pathogenesis of infectious diseases. J Infect Dis 218(Suppl 1):S7–S11. https://doi.org/10.1093/infdis/jiy083.
19. Fedson DS. 2018. Clinician-initiated research on treating the host response to pandemic influenza. Hum Vaccin Immunother 14:790–795. https://doi.org/10.1080/21645515.2017.1378292.